#1 Clinical Trials Search in Europe

Censavudine

Censavudine, also known as TPN-101, is being studied in clinical trials as a potential treatment for Aicardi-Goutières Syndrome (AGS), a rare genetic disorder affecting the brain and immune system. This article explores the ongoing research on Censavudine’s safety and effectiveness in AGS patients, providing insights into the trial’s objectives, eligibility criteria, and expected outcomes.

Table of Contents

What is CENSAVUDINE?

CENSAVUDINE, also known as TPN-101, is a new medication being studied for the treatment of Aicardi-Goutières Syndrome (AGS)[1]. It’s important to note that CENSAVUDINE is still in the experimental stage and is not yet approved for general use. The drug is also known by other names, including BMS-986001, Festinavir, and OBP-601[1].

CENSAVUDINE comes in the form of a powder that is mixed into a solution for patients to take by mouth[1]. This makes it easier for patients of all ages to take the medication, including children.

What is Aicardi-Goutières Syndrome (AGS)?

Aicardi-Goutières Syndrome (AGS) is a rare genetic disorder that affects the brain and immune system[1]. It typically starts in infancy and can cause severe neurological problems. Some common signs of AGS include:

  • Developmental delays
  • Muscle stiffness (spasticity)
  • Abnormal movements
  • Small head size (microcephaly)
  • Calcifications in the brain
  • White matter abnormalities in the brain
  • Brain shrinkage (atrophy)
  • Irritability, feeding and sleeping difficulties
  • Unexplained fevers
  • Skin lesions on fingers, toes, and ears

AGS is caused by mutations in specific genes, including TREX1, RNASEH2A, RNASEH2B, RNASEH2C, and SAMHD1[1]. These mutations lead to an overactive immune response, particularly involving substances called interferons.

How CENSAVUDINE Works

CENSAVUDINE is designed to target the underlying mechanisms of AGS. While the exact details are still being studied, researchers believe that CENSAVUDINE may help reduce the overactive immune response seen in AGS patients[1].

The main goal of the treatment is to lower what’s called the “interferon (IFN) score.” This score measures the activity of certain genes that are overly active in AGS. By reducing this score, CENSAVUDINE may help alleviate some of the symptoms and progression of the disease[1].

Clinical Trial Details

The clinical trial for CENSAVUDINE is a Phase 2a study, which means it’s still in the early stages of testing in humans[1]. Here are some key points about the trial:

  • It’s designed to test both the safety and effectiveness of CENSAVUDINE in AGS patients.
  • The trial will include patients of various ages, from young children to adults.
  • Participants will take CENSAVUDINE for up to 48 weeks (about 11 months).
  • The maximum daily dose is 400 mg[1].
  • Researchers will measure various factors, including the interferon score, drug levels in blood and spinal fluid, brain blood flow, and overall clinical status.

Eligibility Criteria

Not everyone with AGS can participate in this trial. Here are some of the main criteria for eligibility[1]:

  • Participants must have a confirmed genetic diagnosis of AGS with mutations in specific genes.
  • They must have an elevated interferon score in their blood.
  • Different age groups are eligible: adults (18 and older), adolescents (12-17), and children (1-11 years, weighing at least 10 kg).
  • Patients cannot be currently taking certain other medications, including other antiviral drugs or corticosteroids.
  • Participants must not have had any major surgeries within 30 days before the trial or have any planned during the study.
  • Certain medical conditions, such as HIV, active hepatitis, or cancer, may exclude participation.

Safety and Side Effects

As CENSAVUDINE is still in the testing phase, all potential side effects are not yet known. The clinical trial is designed to carefully monitor for any adverse effects[1]. Patients in the trial will be closely watched for:

  • Any new symptoms or worsening of existing symptoms
  • Changes in blood tests, including liver and kidney function
  • Changes in heart rhythm (monitored by ECG)
  • Any signs of allergic reactions

It’s important to note that participation in a clinical trial always carries some risks, but also offers the potential for benefits and contributes to medical knowledge.

What to Expect During the Trial

If a patient participates in this trial, they can expect[1]:

  • Regular check-ups and medical tests
  • Blood draws to measure drug levels and monitor the interferon score
  • Possible spinal fluid tests (optional)
  • Brain scans (MRI) to measure blood flow in the brain
  • Tests to assess overall health and function, including developmental assessments for children
  • Daily administration of CENSAVUDINE as an oral solution

The trial aims not only to test the safety of CENSAVUDINE but also to see if it can improve the symptoms and quality of life for people with AGS.

Aspect Details
Drug Name Censavudine (TPN-101)
Condition Aicardi-Goutières Syndrome (AGS)
Trial Phase Phase 2a
Main Objective Demonstrate proof-of-mechanism and assess safety/tolerability
Primary Endpoints Reduction in IFN score, incidence/severity of adverse events
Secondary Endpoints Drug concentrations, biomarkers, brain imaging, clinical status
Participant Age Range 1 year to adult
Treatment Duration Up to 48 weeks
Administration Oral solution, max 400 mg daily

FAQ

  • What is Aicardi-Goutières Syndrome (AGS)? Aicardi-Goutières Syndrome (AGS) is a rare genetic disorder that affects the brain and immune system. It typically causes early-onset encephalopathy, psychomotor delay, and various neurological symptoms. AGS is characterized by an overactive immune response, particularly involving interferon signaling.
  • What is the main goal of the Censavudine clinical trial for AGS? The main goal of the Censavudine (TPN-101) clinical trial is to demonstrate its proof-of-mechanism in AGS patients by reducing the interferon (IFN) score, which is a measure of immune system activity. Additionally, the trial aims to assess the safety and tolerability of Censavudine in AGS patients.
  • Who is eligible to participate in the Censavudine clinical trial? The trial includes patients with a molecular diagnosis of AGS due to specific genetic mutations, ranging from 1 year old to adults. Participants must have an elevated interferon score and a clinical syndrome consistent with AGS. There are specific criteria for each age group, and certain medical conditions or treatments may exclude participation.
  • How is Censavudine administered in the clinical trial? Censavudine is administered as a powder for oral solution. The maximum daily dose in the trial is 400 mg, and the treatment period can last up to 48 weeks.
  • What are the primary outcomes being measured in the Censavudine trial? The primary outcomes of the trial include the reduction in innate immune signaling, measured by the expression of 24 interferon-stimulated genes (ISGs) in whole blood, and the incidence and severity of treatment-emergent adverse events (TEAEs) over the 48-week treatment period.

Ongoing Clinical Trials on Censavudine

  • Study on the Safety of Censavudine (TPN-101) for Patients with Aicardi-Goutières Syndrome

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

Glossary

  • Aicardi-Goutières Syndrome (AGS): A rare genetic disorder affecting the brain and immune system, characterized by early-onset encephalopathy, psychomotor delay, and an overactive immune response.
  • Interferon (IFN) score: A measure of immune system activity, calculated based on the expression of 24 interferon-stimulated genes (ISGs) compared to healthy controls.
  • Encephalopathy: A general term for any disease or disorder that affects the structure or function of the brain.
  • Psychomotor delay: A slower than normal rate of development in thinking, language, or motor skills in children.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effectiveness.
  • Cerebrospinal fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, protecting them and providing nutrients.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • Lumbar puncture (LP): A medical procedure where a needle is inserted into the lower back to collect cerebrospinal fluid for testing.
  • Magnetic Resonance Imaging (MRI): A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the body's internal structures.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-censavudine-tpn-101-for-patients-with-aicardi-goutieres-syndrome/